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Abstract
Background: Population screening might provide a mechanism to enable early detection of dementia. Yet the
potential benefits, harms or acceptability of such a large-scale intervention are not well understood. This research
aims to examine the attitudes and preferences of the general public, health care professionals, people with dementia
and their carers towards population screening for dementia.
Methods: A systematic review of the international literature was undertaken. A search of fifteen bibliographic
databases was conducted (up to 12 July 2012; no language restriction) using terms related to dementia, screening,
specific screening tools, case finding, and attitudes and preferences; genetic screening and biomarkers were excluded.
All study designs were included except opinion-based papers. Included papers were doubly quality assessed and
thematically analysed using NVivo.
Results: 29,910 papers were identified of which 29 met the inclusion criteria. We identified seventeen themes
relating to the 3 phases of the screening process (pre-, in- and post-screen) – none emerged as more of a facilitator
than a barrier to the acceptance of dementia screening. Seven themes emerged in relation to the patient, carer and
general population: existing health state; lifestyle and life view; awareness of dementia; role of clinician; communication;
benefit; and role of the family. Ten themes emerged in relation to the clinician and healthcare professional: patient’s
existing health and comorbidities; awareness of dementia; confidence; duration of patient contact; suitability of
screening tool; cost; disclosure; time; treatment and prognosis; and stigma.
Conclusions: As for all screening programmes, screening for dementia raises complex issues around preference
and choice for clinicians and the public, and it is unclear what specific factors promote or reduce screening
acceptance the most. Overall, the level of evidence is low, few large scale studies have been undertaken and none
were conducted in representative samples, all affecting the generalizability of identified themes across healthcare
contexts. Nevertheless, our findings suggest that population screening for dementia may not be acceptable to
either the general public or health care professionals, and highlight where focused efforts are needed to gain
insights into dementia specific issues.
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Background
Dementia is a condition of chief importance to ageing soci-
eties in terms of impact and cost, and it’s timely detection
a clinical, research, and political priority. In a recent UK
Department of Health report [1] it was estimated that 45 %
of patients who might meet the criteria for dementia in
any given population still do not receive a formal diagnosis
or receive it too late to be clinically useful. Systematic
population-level screening (a process of identifying a con-
dition amongst a population of apparently healthy individ-
uals) has been suggested as a possible mechanism to
enable early detection of dementia in people who may be
at increased risk [2–5]. Currently guidance produced by
the UK National Screening Committee [6], the Royal
Australian College of General Practitioners [7] and the US
Preventative Services Task Force [8] advises against the
adoption of screening for the early detection of dementia
and cognitive impairment because there isn’t enough evi-
dence to ensure the overall benefits of the screening jour-
ney would outweigh the harms [6, 9, 10].
We conducted a review of the literature to systematic-
ally address one specific screening criterion proposed by
Wilson and Jungner [10] (Additional file 1) and the UK
National Screening Committee [6]; “that the test should
be acceptable to the population”. We broadened the
concept of acceptability to include perceived risks and
benefits arising from population screening, as well as atti-
tudes, preferences and values of patients, carers, the general
public and health care practitioners. Appraising accept-
ability broadly is important because it can reveal critical
equity, ethical and social issues relevant to the develop-
ment of new screening programmes, and highlight how
informed choice, confidentiality and respect for autonomy
might be ensured. Furthermore, these views are likely to
impact on decision-making processes, compliance with
the programme and ultimately the expectations placed
upon a screening programme in terms of effectiveness
and cost effectiveness. The current systematic review of
the scientific literature is the first to evaluate the attitudes
and preferences of the general public and health care pro-
fessionals regarding population screening for dementia.
Methods
To ensure transparent reporting on how we selected
and analysed the literature, this review meets PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses; http://www.prisma-statement.org) guide-
lines [11] (Additional file 2) and was conducted according
to a pre-defined protocol (Additional file 3).
Search strategy
The search strategy was developed with input from clini-
cians, health scientists and an information specialist.
Electronic searches of bibliographic databases conducted
on 16th July 2012 include: (1) terms relating to dementia;
(2) terms relating to screening and case finding; and (3)
terms related to attitudes and preferences. The search
strategies covered all types of dementia, had no time or
language limits, and were applied to the following data-
bases: MEDLINE, EMBASE, CINAHL, CDR, Cochrane
and Campbell Collaboration databases; PsycINFO, Social
Sciences Citation Index, Web of Science, Bibliomap,
DoPHER, TRoPHI. Reference lists of all included studies
were scanned for relevant articles. The Medline search
strategies for patients, carers and health care practitioners
are presented in Additional files 4 and 5.
Inclusion and exclusion criteria
Studies where the primary or secondary objectives were
to explore, describe or explain the attitudes and prefer-
ences to screening for dementia (from the point of view
of health and social care professionals, members of the
general public, people with dementia, informal or formal
carers) were included irrespective of their age, education,
cognitive or dementia diagnostic status, or the setting in
which the study was conducted. In addition, studies that
assess health professionals’ perceptions, views and expe-
riences were also included.
All study designs (qualitative, quantitative randomized
experimental, quantitative non-randomized controlled,
quantitative observation, and mixed methods) were eli-
gible for inclusion. Opinion-based papers were excluded.
Only published sources were considered.
Not all screening tests were considered for inclusion.
This review only includes pen and pencil tests or any tests
that can currently be easily administered in primary or
community care settings to screen for dementia. We did
not consider screening procedures that involve genetic
tests or biomarkers. This is because such tests are being
researched as potential pre-dementia “diagnostic” tests or
as post-dementia diagnostic subtyping tests. Therefore
they are not at present suitable for use as screening tests
for the dementia syndrome at the population level. We
also excluded screening to detect persons with MCI (Mild
Cognitive Impairment) who do not meet the criteria of de-
mentia, because MCI is variably defined and there is a lack
of clarity around diagnosis of this condition [12].
Outcomes
Primary outcomes - Perceptions, views and/or attitudes
and/or experiences of patients and carers, and health
and social care professionals were analysed with particu-
lar attention given to 1) their experience of screening
(receiving or administering), 2) their view of population
screening as an intervention (positive, negative), 3)
quotes in support of views and perspectives, and 4) out-
comes (views considered by authors as being associated
with positive or false negative results).
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Secondary outcomes - Ethical, moral and cultural issues;
practical implications in terms of knowledge, organisation
of health and social care (e.g. accessibility of diagnosis
services, information and support; etc.), resources and
funding in the context of the perception of patients,
carers and practitioners.
Identification of studies
All the citations identified in the search were down-
loaded into EndNote and screened for inclusion by two
reviewers, who worked independently. All titles and
abstracts were screened for inclusion by Steven Martin
and Louise LaFortune. The full text of articles identified
as either relevant or possibly relevant from the title and
abstract were obtained and assessed to determine whether
it met the inclusion criteria. Native speakers assessed non-
English papers. Discrepancies between the authors were
resolved via discussion at both stages. As screening for
dementia may be part of a diagnostic process a number of
relevant papers related to diagnosis of dementia were in-
cluded up to full paper stage to examine if any references
to population screening were made.
Quality assessment
Two reviewers independently assessed study quality
using a checklist adapted by Bunn et al. [13], building on
the Spencer et al. [14] framework for assessing quality;
the overall reliability and usefulness of the study to the
research questions was graded as low, medium or high.
We included all studies regardless of their quality. As a
broad range of study designs have been used in this area
of healthcare, the use of a single checklist, in contrast to
individual checklists for each study design, was consid-
ered more appropriate.
Data extraction
A data extraction form was developed and tested by two
authors (SM, LL). Data were then extracted by two au-
thors (SM and SK). A summary of data extracted can be
found in Tables 1 and 2, full data extraction is located
online in supplementary material (additional file 6).
Data analysis
Two approaches to analysis were adopted. A thematic
approach [15] was used to analyse people’s (patients’,
carers’, the general public’s and health professionals’) atti-
tudes, behaviours, value systems, concerns and perceptions
with regard to screening for dementia. Questionnaire and
survey data were extracted and summarised. Source data
management and thematic analysis was carried out within
the computer-assisted qualitative data analysis software,
NVivo (version 9.2) and Excel. Two researchers independ-
ently coded the data (SM and SK). The data was coded into
topic areas and then further analysed and developed into
themes. Where there were differences between the re-
searchers, themes were further discussed and agreed. Due
to the predominantly qualitative nature of the data, and
the presence of clinical, methodological and statistical
heterogeneity, it was not appropriate to conduct a meta-
analysis. This approach supports our purpose because it in-
volves discussions to establish consensus on the format of
data extraction and extraction of data around key themes.
A further advantage is the opportunity it provides to revisit
the context of the quotation within a study very easily. This
means that the exact content of the discussions are exam-
ined more closely and different aspects of a ‘dense’ para-
graph of data can be assigned to several themes.
A narrative synthesis of data from all included studies
was undertaken by SM. This was done to provide a de-
tailed summary and comparison of attitudes and prefer-
ences across studies. We then analysed the findings and
discussion sections of the papers by identifying key themes
represented in data (i.e. quotations) and the statements
made within the discussion. We did not adopt a line-by-
line analysis in which codes are assigned to each line of
text as we did not feel that such intense scrutiny of con-
tent would have enhanced our collection of descriptive
and interpretive data. To deal with the apparent subjectiv-
ity of the process, the themes identified by both reviewers
were compared and discrepancies were discussed. This
approach to data extraction increases the likelihood of
achieving data saturation [16, 17].
Data were divided into two broad categories a) themes
impacting on the attitudes and preferences of patients,
carers and the general public, and b) themes impacting
on the attitudes and preferences of clinicians and health-
care professionals. Data was organised in this way because
the available evidence derives from these populations.
There was therefore no need to pre-conceive groupings.
We paid particular attention to i) whether someone
had been screened for dementia or had a diagnostic
assessment for dementia which could have influenced
their perceptions of the potential harms and benefits of
screening, and ii) whether the type of tests and/or set-
ting influences perceptions of physicians with respect to
the acceptability, potential harms and benefits of screen-
ing for dementia; iii) the year the study was published to
detect potential trends over time.
Results
Search results
The database searches generated 20,678 titles (Fig. 1),
which were then screened for inclusion. Given the broad
use of the terms screening and diagnostic, we carefully
assessed 720 abstracts and the full text of 185 papers. In
addition, three additional papers were identified from
hand and grey literature searches. We included 29 studies
looking at attitudes and/or preferences towards screening
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for dementia. The reasons for exclusion, at full paper,
were: not about screening (n = 146), including 15 reviews
that did not examine dementia screening, not primary
research (n = 11); unobtainable (n = 2). Three non-English
language papers were translated but excluded at full paper
sift [18–20].
Sample characteristics
Nine papers involved patients or people with dementia
in their research. A total of 2,575 patients or people
with dementia were included in this review. Two studies
involved a total of 331 carers in their research. Study
sizes ranged from 81 to 250. A number of studies
reported unclear sample sizes. There were no studies
based on samples representative of the general popula-
tion; however, five studies were based in the community
and had participants recruited from the general public.
In total 1,977 people from the general public were
included in this review (study sizes ranged from 125 to
1,039 people).
Health care professionals constituted the largest group
of participants in the identified studies. Fifteen studies
included a total of 5,132 clinicians or health care practi-
tioners. One paper did not provide a clear description of
the study sample. Number of participants ranged from
four to 1,473. General practice, including both general
practitioners and practice nurses was the most frequent
research setting (11 studies). Settings for the remaining
studies with healthcare professionals included: commu-
nity nursing, geriatric specialists, community mental
health, emergency department, outpatient clinic and uni-
versity – one in each.
Table 1 Summary table of included studies
First Author Country N. Population Study type Quality rating
Boise L (2010) USA 199 Clinicians and medical assistants Intervention Medium
Boise L (1999) USA 78 Primary care physicians Focus groups High
Bond J (2010) EU Not reported Clinicians, payers and general public Survey High
Borson SJ (2007) USA 26 Medical assistants Intervention High
Boustani M (2011) USA 206 Caregivers and non-caregivers Survey High
Boustani M (2008) USA 315 Primary care patients’ Survey High
Boustani M (2003) USA 318 Older adults Survey High
Brodaty H (1994) Australia 1473 General practitioners Survey Medium
Bush C (1997) USA 360 Primary care physicians Survey Medium
Cahill S (2008) Ireland 307 General practitioners Survey Medium
Carpenter CR (2011) USA 55 Physicians and Nurses Survey Medium
Dale W (2006) USA 149 Adults Survey Medium
Dale W (2008) USA 199 Older adults Intervention Medium
Downs M (2000) UK 278 General practitioners Survey High
Fowler R (2012) USA 554 Primary care patients’ Survey High
Galvin JE (2011) USA 1024 Health care professionals Pre-post test High
Galvin JE (2008) USA 1039 Older adults Survey Medium
Hansen EC (2008) Australia 24 General practitioners Focus groups Medium
Holsinger T (2011) USA 345 Primary care patients’ Survey High
Iliffe S (1994) UK 412 Older adults Survey Medium
Iliffe S (2003) UK 247 Health care professionals Workshop and survey Medium
Iracleous P (2010) Canada 249 Primary care physicians Survey Medium
Justiss MD (2009) USA and UK 245 Older adults Survey High
Krohne K (2011) Norway 18 Older adults Observational Medium
Lawrence JM (2003) USA 787 Clinicians and community-dwelling individuals Intervention and survey Medium
Manthorpe J (2003) UK Not reported Health care professionals Workshop and survey Medium
Martinez-Lage P (2010) EU 500 Physicians Survey Medium
Welkenhuysen M (1997) Belgium 167 Medical students Survey Medium
Williams CL (2010) USA 119 Adults Interview Medium
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Study characteristics
Studies took place in Australia (n = 3), Belgium (n = 1),
Canada (n = 1), Ireland (n = 1), Norway (n = 1), UK
(n = 5) and USA (n = 15). One study had both UK and
USA sites and two studies were based across five
European countries (France, Germany, Italy, Spain and
the UK). The oldest included study was published in
1994, the most recent published in 2012. In most cases
the ‘test’ was hypothetical, or described in very general
terms (i.e. a screening test). No studies were included
which examined the attitudes and preferences, or
acceptability of a specific existing tool. There were a
range of quality ratings; 18 studies were rated as
medium quality and 11 were rated as high (Table 1).
Full quality assessment scores are presented online in
the supplementary evidence (Additional file 7).
Risk of bias
Due to the heterogeneity of included studies the pooling
of results is inappropriate for this review. Given that
qualitative data were extracted no test to assess homo-
geneity (e.g. chi-squared test for homogeneity, I2, ran-
dom effects model, Egger regression test, Hedges-Olken)
is appropriate. Sources of financial support for included
studies can be found on line in supplementary material
(Additional file 7).
Attitudes and preferences
Three stages of the screening process were identified: a)
the pre-screen period, b) the in-screen, and c) the post-
screen period. At each stage of the screening process a
number of factors impact on an individuals’ decision to
screen or be screened, and are relevant to the acceptabil-
ity of population-level screening for dementia (Fig. 2).
Seven key themes emerged from studies with the pa-
tient, carer and general population: 1) existing health
state; 2) lifestyle and life view; 3) awareness of dementia;
4) role of clinician; 5) communication; 6) benefit. Ten
key themes emerged in relation to the clinician and
healthcare professional: 1) patient’s existing health and
comorbidities; 2) awareness of dementia; 3) acceptability;
4) duration of patient contact; 5) screening tool; 6) cost;
7) disclosure; 8) time; 9) treatment and prognosis; 10)
stigma. These themes emerged repeatedly in the peer-
reviewed literature and are discussed below.
Themes in relation to the patient, carer and general
population:
Existing health state Survey data [21] found that being
healthier (as indicated by taking fewer than three medi-
cations) was associated with less willingness to accept
dementia screening and that having some type of cogni-
tive difficulty was associated with more willingness to be
screened for dementia. A qualitative study [22] also
showed that a person’s existing health state and per-
ceived susceptibility to illness may impact on the accept-
ability of screening for dementia and on ability to
undergo screening tests, as exemplified in the following
quote:
“It wasn’t that it couldn’t be done, but at my age… I
got tired – this is a weariness I carry with me
everywhere (and it kicks in every time) I’m exposed to
something complicated.” [22]
Lifestyle and life view The data on lifestyle and views
of patients are predominantly derived from survey re-
sponses. Surveys consisted of validated scales and items
designed by the research teams. No studies contained
substantial qualitative components. While some data
[23–27] suggest that some respondents have no con-
cerns and are pleased to have their memory evaluated,
other results [21] suggest that few people would agree to
routine screening for memory problems for reasons such
as stigma [28–30]. It is important to take note that no
patient or carer mentioned the word stigma; this word
was adopted by researchers in their attitudinal scales.
Awareness of dementia There are issues around aware-
ness and public education [31]. The quotations below
Table 2 Summary of themes in included studies
Theme Reference
Pre-screen
Stigma and awareness of
disease
22, 24, 27, 29, 30, 31, 33, 34, 35,
36, 38, 39, 43, 43, 47, 50
Role of family 27, 31, 32, 34, 36, 37, 38, 39
Existing health 22, 27, 31, 34, 36, 40
Health insurance/financial/
Employment/driving
21, 28, 35, 43
Duration of contact 46
Locality 37, 46
Current practice/practicalities 36, 38, 40, 42, 44, 45, 49, 50
Lifestyle and life view 21, 24, 26, 27, 28, 29, 33, 37, 48, 50
Training 22, 31, 34, 36, 39, 47, 49, 50
In-screen
Time constraints 36, 41, 44, 45, 46
Inaccuracy of test 41, 45
Cost 38, 45
Communication 22
Post-screen
Lack of change in prognosis,
treatment and patient benefit
21, 23, 24, 26, 27, 28, 29, 31, 32, 33, 35,
36, 37, 38, 39, 41, 42, 44, 45, 47, 48, 49
Role of support 30, 37
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illustrate that some individuals have a low level of
awareness regarding the screening test. In these cases
there have been some misunderstandings around both
the reasons for a screen and the implications of test
results [22, 31, 32]. While we are unable to say what
proportion of individuals have not fully understood or
poorly interpreted the screening test, it is the responsi-
bility of health care professionals to raise the issue and
ensure consent is given.
“It [the screening test] is probably to do a little bit of
research on what we remember, and… if our heads are
where they are supposed to be…” [22]
“…she tested my head, that’s what she did.” [22]
“I got the impression that I passed the test. Yes. Or you
could say it was examination questions, right?” [22]
Role of clinician This theme emerged from two studies,
and as the quote below shows, a person’s acceptance of
dementia may be influenced by the role of the clinician
[32]; “It’s okay to be screened’cause then [the occupa-
tional therapist] gets to see what I really need help to do”
[22]. A clinician needs to engage with the individual to
outline what their role is, how they will conduct the test
and what the outcome may be, essential preparatory
work in order to manage patient experience and
expectations.
Communication In one study [22] a number of patients
reported uncertainties around the test and some of
these individuals were unable to recollect the screening
was explained to them beforehand, or how the results
were presented afterwards. While we cannot substanti-
ate that poor communication on behalf of clinicians is
responsible for levels of confusion, the patients’ were
still reliant on their own interpretation of the screening
test, its purpose and the potential outcome. The pa-
tients also reported screening to be strenuous or stress-
ful, mostly due to a perceived pressure to perform well
on the test.
“No, I wasn’t told. I don’t know.” [22]
“[I]f I was to guess (…) it has something to do with
memory?” [22]
Fig. 1 Flow of information through different phases of the systematic review
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Benefit Where data is available [22, 26, 28, 30, 33, 34]
it seemed that caregivers and the general public believe
there are a number of benefits to screening for dementia,
including treatment and financial benefits. However, in
one study [35] nearly half of the patients who screened
positive for cognitive impairment refused a diagnostic
evaluation.
“I’m over 50 with no children. I need to know how to
be prepared.” [34]
“[they can] catch it before it’s too late.” [34]
Studies that reported the ability of families to plan and
make arrangements are often cited but, little qualitative
evidence was found to support this claim. Most evidence
is derived from questionnaire responses.
Role of family There was good evidence to suggest that
the family plays an important role in decisions whether
or not to undergo screening [24, 31, 32, 34, 36–39].
The influence of the family is dynamic and can include
influencing decisions to consult health care profes-
sionals in primary or secondary care. The family may
also act as a prompt, recognising that an individual
may have issues related to the onset of the disease. The
quote below is from the perspective of a primary care
physician, discussing how important the family is to the
patient when deciding whether or not to consult or
undergo screening.
“I’d say in 90 % of the cases it’s the family [that brings
the dementia to my attention].” [36]
Themes in relation to healthcare professionals:
Patient’s existing health and comorbidities Four stud-
ies [30, 34, 36, 40] showed that in most cases the doctors
felt that the individual was too ill to proceed with a full
assessment or to use screening instruments. The clini-
cians tend to address other more easily treatable issues
first rather than the dementia because they report mak-
ing more impact.
“When we do see people for dementia, it is common
that they have ten other medical problems. There’s
usually something else going on - dementia or memory
problems is right at the bottom of the list, in terms of
things to address.” [34]
Awareness of dementia Lack of awareness of dementia
on the part of healthcare professionals was reported to
be a barrier to recognising symptoms. Studies [36, 39]
found that the primary barriers were symptom recogni-
tion, physician attitudes, and constraints in contemporary
medical practice. It appears that whilst the presentation
and recognition of symptoms do not impact on decisions
to screen (individuals are asymptomatic at point of test) it
is the attitudes, rather than knowledge, which may deter-
mine whether physicians conduct a full assessment.
Acceptability Two studies [35, 41] found that accept-
ability levels for screening was high in staff members,
conversely a number of studies [33, 39, 42, 43] asked cli-
nicians and other HCPs and found that clinicians were
undecided or negative when asked if cognitive screening
Fig. 2 1) Pre-screen, in-screen and post-screen refers to three stages of the screening process. 2) Each box represents themes that emerged
repeatedly from analysis for public/carers and health care professionals
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in primary care would lead to better outcomes. In one
study, female clinicians were more likely to have a posi-
tive attitude towards screening [44].
Duration of patient contact Our findings suggest that
clinicians may not feel confident about screening people
with whom they have little or no relationship [36, 45];
conversely they also feel some apprehension towards
screening patients with whom they have had a long rela-
tionship [34, 45]. The finer detail of why this may be the
case was not presented in the literature, but there could
be a number of possibilities including issues around lack
of understanding of prognosis, poor treatment options,
lack of transparent care pathways etc. The quotes below
illustrate these points well:
“I know I’m guilty of it, and suspect the rest of us are
too . . . which is that, with someone who’s been your
patient for a while and, you haven’t done a Mini-
Mental State Exam on them…” [45]
“Very often you know these patients very, very well and
have seen them over many years … and maybe you
don’t notice, because of your lack of memory … their
lack of memory and then it’s really only when a crisis
occurs… something happens that sort of makes
everybody stand back and say ‘Oh my God, it’s really
obvious’ and made it difficult for most to administer
the MMSE (Mini Mental State Examination).” [45]
The screening tool The lack of acceptable and accurate
screening tools also provides a barrier to population
screening for dementia for the general population [45–48].
In one study [48] both generalists and specialists re-
ported that screening inaccuracy was the most import-
ant reason for not undertaking routine screening at age
65. When clinicians and health care professionals were
asked about their preferences regarding tools, tests such
as clock drawing [46] and the short Blessed [47] were
identified.
“The MMSE is quite distressing… to do with a patient
you know, I think it’s quite an invasive test… I think
part of the problem is that the minute you start doing
it, it’s…very direct.” [45]
Cost There were a number of practicalities that made
screening for dementia problematic, including the cost
[38]. Cost concerns from clinicians were related to im-
plementation, disruption to current working practices as
well as costs of additional staff and/or infrastructure
[38]. Costs concerns from patients included rising health
and travel insurance and other benefits. Costs of direct
care and financial implications of indirect care were also
discussed.
Disclosure Screening involves communicating the out-
come to the patient so issues of diagnosis disclosure in-
evitably arise. The difficulties were perceived as closely
connected with a clinician’s duration of contact with
their patient, with particularly problematic implications
around lack of prognosis, poor treatment options, a lack
of transparent care pathways and the patient’s existing
state of health [30, 43, 46]. Evidence suggests that clini-
cians believe interventions are “timely” when required
in response to a patient’s functioning or cognition
prompting them to present to medical attention, rather
than an approach that encourages disclosure to all re-
gardless of their existing needs [36, 37, 49]. Importantly,
the identification of dementia was perceived as poten-
tially harmful to some patients [37]. The following
quotes illustrate the point:
“I’ve walked out of the room lots of times going ‘I think
something’s going on here but not pushed it, because
what am I going to do? What am I going to tell the
family?’ Well, they’re functioning okay in the home, I
think they’ve probably got early dementia, but is it
going to change anything? No. Can I do anything
about it? No. So, why get everybody all excited when
we’ll just keep a close eye on it.” [36]
“The family doesn’t want to hear, the patient doesn't
want to hear. The ‘gradual decline of forgetfulness’
is a much better description to the patient and the
family.” [36]
Time Lack of time to screen was a common theme that
emerged in the literature [36, 41, 45]; however, in the
single study [35] that examined the impact of a screen-
ing intervention on practice, none of the staff reported
significant disruption to existing working practices.
Treatment and prognosis Attitudinal barriers included
the perception that nothing could be done for patients
with dementia [34, 41, 49, 50] given the limited effective-
ness of currently available treatments. It appears that for
many clinicians, until there are effective treatments,
there is little reason to assess patients for cognitive
problems. A major finding [23] was the reluctance of
clinicians to follow-up on a positive dementia screen.
Clinicians often determined that the symptoms did not
warrant a dementia work-up.
“Sounds like there’s some message coming from
somewhere [that doctors should be more] aggressive
with early diagnosis… If that’s the case that needs to
be communicated with some really good reasons. To
offset the ‘I don’t want to know, the family doesn’t
want to know…’ There [needs to be] something that
changes the prognosis.” [36]
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Stigma Some clinicians recognised the stigma associated
with dementia and with Alzheimer’s Disease specifically.
This finding may reflect the lack of effective available
treatment options and the level of disease awareness in
the population [30,36.38].
“I have the most trouble discussing with the patients
and families. I have no problem about cancer or other
fatal diseases, but Alzheimer’s disease has a huge
stigma associated with it.” [36]
Differences between patients, public and clinician views
For patients, the key factors that impact on the accept-
ability of screening for dementia relate to the individ-
ual’s context such as their current health, lifestyle, life
view and their knowledge of dementia. Where evidence
does exist, patients have not been shown to consistently
recollect either the screening test or the result, which
raises ethical issues around consent and disclosure.
Three themes – awareness, role of the clinician and
communication – may potentially empower the patient
to make informed choices which impact on their long-
term health outcomes. For clinicians, a number of con-
textual issues (including current practice, poor progno-
sis, lack of treatment options, stigma and the duration
of contact with the patient) and mechanisms (including
the practicalities, awareness, confidence, accuracy of
tools, cost, time, a patient’s existing state of health and
issues around disclosure) appear to impact on accept-
ability and decisions to screen. Whilst the public are
more concerned about what use a screening test will be
to them immediately and in the short-term, clinicians
have some paternalistic/protective concerns over the
long-term impact of dementia screening. Awareness of
dementia is important to patients, carers and health
care practitioners.
Discussion
Summary of main results
This systematic review is the first to evaluate the
attitudes and preferences of people with dementia, their
carers, and the general public and health care profes-
sionals regarding population screening for dementia. We
identified a relatively small number of papers despite
using a broad search strategy.
At each stage of the screening process – before, during
and after screening – a number of attitudinal factors im-
pact on decisions about screening and the acceptability
of population-level screening for dementia. However,
not all these themes are expected to contribute equally
in every situation since people make choices and take
decisions according to their own values, experience and
context.
Strengths and limitations
The key strength of this review pertains to the extensive
literature searches, entailing multiple search strategies
for carers, patients and healthcare professionals and also
including grey literature, which means we are confident
that most of the published evidence has been captured.
The analytic framework adopted in this review facilitated
categories/themes to emerge from multiple sources of
data and then an examination of the interrelations
among these themes. There are, however, a number of
weaknesses, related namely to the available evidence
which impact on the generalizability of our findings.
Most studies have been undertaken in the USA and
Canada, including some in the general population, how-
ever, results are mixed. Factors that appear to impact on
the acceptability of a screening programme include
stigma, misconceptions and poor levels of awareness
around disease combined with the knowledge of poor
prognosis and few treatment options; however, due to a
relatively small number of papers of limited quality
themes might be incomplete. Other factors included
health insurance and other financial implications, and
impacts on employment and driving. Evidence also sug-
gests that a person’s lifestyle and attitude to health plays
a role in decisions to screen. The perception and impact
of stigma is a concern to patients, carers, the general
public and health care professionals; however it is diffi-
cult to conclude from the literature identified to what
extent the findings under individual themes (e.g. accept-
ability, disclosure) can be explained, at least in part, by
underlying or unrecognised stigma. These findings may
suggest that the stigma around Alzheimer’s disease and
dementia requires tackling through education before a
national screening programme could be developed and
successfully implemented. Studies were examined to as-
sess if there are any differences in the people’s attitudes
toward dementia screening between the older studies
and those more recent ones; however no differences
were found. Economic costs are an important factor in
determining the adoption of screening for dementia at
policy level. This research team conducted a systematic
review to assess the cost implications of screening for
dementia - results will be published shortly.
No study was identified which assessed the attitudes
and preferences of a sample representative of the UK
general population. A number of small studies (n = 5)
have been conducted in the UK which surveys the atti-
tudes and preferences of health care professionals. These
participants reported they saw small patient benefits
through poor prognosis and few treatment options as
impacting on the acceptability of a screening programme
for dementia. Current practice, time constraints and
practicalities of screening, as well as a patient’s existing
health, also impact on decision-making. There are
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further issues around which tool is most appropriate to
adopt. Current work, using a participant and public
involvement strategy or adopting a qualitative research
design, has examined more closely the findings of this
review and contextualised them for a UK audience (soon
to be published).
The level of evidence is quite low and few large-scale
mixed-methods studies have been undertaken. In this
review one medium quality study [19] provided substan-
tial qualitative data on the attitudes and preferences of
patients; and another high quality study [32] provided
substantial qualitative data on the perspectives of health
care practitioners. However, this brings a number of
limitations including the contextual dependency and
generalizability of the findings. While the attitudes and
preferences reported in these studies may be credible
and valid in the samples they recruited, their transfer-
ability to other populations remains unknown. While the
review demonstrates that the acceptability of dementia
screening found in different studies may vary, the mag-
nitudes of these variations and their impact on screening
decisions are difficult to determine. Findings may also be
influenced by the prior views of researchers, though the
dual structured process of paper selection, data extrac-
tion and analysis will have guarded against major biases.
Future research may undertake assessments of equipoise
of screening interventions for clinicians and study authors.
Although most of the clinicians and patients involved
in the studies included in this review consider dementia
a serious condition, many questioned the need to iden-
tify it early through population screening. Whilst the
general public may have a more positive opinion of
routine screening, this needs to be contextualised with
other themes such as poor awareness and communica-
tion, and what is expected from the natural progression
of the disease. Members of the general public may be
more positive because they have a poor understanding
of the disease, its natural progression and prognosis.
Conclusions
The published literature on attitudes towards popula-
tion screening for dementia is diverse and fragmented
and it is difficult to draw clear conclusions from the
data. Our review indicates that several factors may
either enhance or limit the acceptability of screening
for patients, carers, the general population, and clini-
cians. Attitudes and preferences are complex and
multi-factorial and our findings suggest that popula-
tion screening for dementia may be acceptable neither
to the general public nor to health care professionals.
Both groups express concerns about the means by
which screening is performed, mutual trust, and uncer-
tain outcomes. Policy makers should be cautious about
the adoption of population screening for dementia
without evidence and careful evaluation of benefits or
risks, as noted by Le Couteur and colleagues [9].
This project highlights where focused efforts are
needed to further our understanding of how to improve
timely detection of dementia in the community. Given
that individual variants appear largely responsible for
decision-making, there needs to be a sensitive approach
to the identification of dementia. This review focuses on
any tests that can currently be easily administered in pri-
mary or community care settings to screen for dementia
yet the public debate should encompass the attitudes
and preferences of the general public and clinicians to-
wards genetic screening for dementia (for which a paral-
lel review is underway). We conclude by arguing that
the challenge for health and social care professionals as
well as policy makers is to engage with their patients
and the public to understand in greater depth their ex-
pectations and perspectives on population screening for
dementia.
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